Drag a card by its title · ⚙ to size, swap or remove

The company

Aprea Therapeutics, Inc.

APRE · Nasdaq

Health CareBiotechnologyNot moving yet

APRE stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 23.4% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation: Not moving yet
Weeks in an uptrend: out for 52
Industry in uptrend: 15% -17 in 4 wk
Insider buys, 12 months: $91K
Insider sales, 12 months: $0
Officials’ trades on record: 0
Institutions holding: 28 (+6)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months4

Sale orders, 12 months0

Buyers · sellers3 · 0

Who	Did	Shares	Traded
Richard PetersDirector	bought	123,915at $0.807	31 Mar 2026filed 1 Apr 2026
Richard PetersDirector	bought	123,915	31 Mar 2026filed 1 Apr 2026
John P. HamillSrVP/CFO/Prin Fin & Acct Ofcr	bought	30,978at $0.807	31 Mar 2026filed 1 Apr 2026
John P. HamillSrVP/CFO/Prin Fin & Acct Ofcr	bought	30,978	31 Mar 2026filed 1 Apr 2026
John P. HamillSrVP/CFO/Prin Fin & Acct Ofcr	bought	5,700at $0.89	30 Jan 2026filed 2 Feb 2026
John P. HamillSrVP/CFO/Prin Fin & Acct Ofcr	bought	5,700	30 Jan 2026filed 2 Feb 2026
Oren GiladPresident/CEO	bought	28,100at $0.89	30 Jan 2026filed 2 Feb 2026
Oren GiladPresident/CEO	bought	28,100	30 Jan 2026filed 2 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders28+6 on the quarter

New · exited8 · 2

Reported value$1.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

Manager	Shares	Change
AIGH Capital Management LLCunchanged · filed 7 Aug 2026	1,015,541$815K	00.0%
Vestal Point Capital, LPunchanged · filed 14 Aug 2026	350,000$281K	00.0%
SPHERA FUNDS MANAGEMENT LTD.unchanged · filed 14 Aug 2026	270,000$217K	00.0%
Nantahala Capital Management, LLCunchanged · filed 14 Aug 2026	205,760$165K	00.0%
RENAISSANCE TECHNOLOGIES LLCadded · filed 13 Aug 2026	105,800$85K	+80,700+321.5%
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 2026	74,869$60K	-44,262−37.2%
CITADEL ADVISORS LLCnew · filed 14 Aug 2026	58,600$47K	+58,600
BNP PARIBAS FINANCIAL MARKETSadded · filed 13 Aug 2026	45,211$36K	+5,394+13.5%
DIADEMA PARTNERS LPnew · filed 14 Aug 2026	44,907$36K	+44,907
VANGUARD FIDUCIARY TRUST COunchanged · filed 13 Aug 2026	38,464$31K	00.0%